Physician profile
Kara Addison
NPI 1295090983
$49,819.29
in general payments reported to CMS, 2019-2025
19 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,363 · 2022: $8,026 · 2023: $12K · 2024: $8,523 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $2,618 · Consulting Fee: $1,780 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,807.50 |
| Food and Beverage | $2,618.45 |
| Consulting Fee | $1,780.00 |
| Education | $224.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,121.27 | 2021-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $8,870.98 | 2022-2025 | Sotyktu |
| Amgen INC. | $7,276.22 | 2021-2025 | Otezla, Otezla |
| Ucb, INC. | $6,957.74 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $5,816.38 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $1,129.11 | 2021-2025 | |
| Janssen Biotech, INC. | $757.30 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $224.98 | 2023-2025 | Dupixent |
| Incyte Corporation | $179.39 | 2022-2025 | Opzelura |
| Genzyme Corporation | $134.41 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $91.34 | 2021 | |
| Genentech USA, INC. | $84.83 | 2021-2025 | Xolair |
| Revance Therapeutics, INC. | $47.88 | 2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.99 | 2024 | Spevigo |
| Leo Pharma INC. | $20.69 | 2025 | Adbry |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.29 | 2022 | |
| Blueprint Medicines Corporation | $16.41 | 2025 | Ayvakit |
| Merz North America, INC. | $15.79 | 2023 | Xeomin |
| Arcutis Biotherapeutics, INC. | $14.29 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Addison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.